Press Releases

    • AUG 06 2018

    Clinical Cancer Research Article Describes Opportunity to Use Imipridones for Brain Tumors

    Philadelphia, PA (July 31, 2018) – Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology. Oncoceutics developed this portfolio of chemical compounds that target G protein-coupled receptors (GPCRs) using the unique core chemical structure of the

    • MAY 29 2018

    Oncoceutics Abstracts at ASCO Highlight Efficacy of ONC201 in High-Grade Gliomas

    Philadelphia, PA (May 29, 2018) – Oncoceutics, Inc. announced that two abstracts will be presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) that will highlight clinical success of the company’s lead compound in treating high-grade gliomas (HGG), including those that harbor the H3 K27M mutation. The first abstract, entitled

    • MAY 17 2018

    Oncoceutics Announces Support for Legislation Increasing Awareness for DIPG

    Philadelphia, PA (May 16, 2018) – Oncoceutics, Inc. announced today its support for legislation that will increase awareness for diffuse intrinsic pontine glioma (DIPG), the most devastating type of brain cancer in children. Oncoceutics supports the efforts of the Jack’s Angels Foundation and Rep. Stephen Knight (CA) to pass H.Res.69 to designate May 17th as

    • APR 16 2018

    Clinical Trial Tests ONC201 in Combination with Ixazomib and Dexamethasone in Multiple Myeloma

    Philadelphia, PA (April 16, 2018) – Oncoceutics, Inc. announced today that the first patient has been treated in a Phase I/II clinical trial of ONC201 in combination with ixazomib and dexamethasone in relapsed and/or refractory multiple myeloma. The trial, led by Ajai Chari, MD, Associate Professor at the Icahn School of Medicine at Mount Sinai,